Repository

Publications

ASO Visual Abstract: Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

van Keulen AM, Buettner S, Olthof PB, Klümpen HJ, Erdmann JI, Izquierdo-Sanchez L, Banales JM, Goeppert B, Roessler S, Zieniewicz K, Lamarca A, Valle JW, La Casta A, Hoogwater FJH, Donadon M, Scheiter A, Marzioni M, Adeva J, Kiudeliene E, Fernández JMU, Vidili G, Mocan T, Fabris L, Krawczyk M, Folseraas T, Dopazo C, Detry O, Voiosu T, Scripcariu V, Biancaniello F, Braconi C, Macias RIR, Groot Koerkamp B.
Ann Surg Oncol. 2024 Jul 12. doi: 10.1245/s10434-024-15745-4
2024 

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population

Rimini M, Fornaro L, Rizzato M, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim J, Abidoye O, Rapposelli I, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon H, Braconi C, Pirrone C, Casadei-Gardini A.
European Journal of Cancer. 2024. 114199. ISSN 0959-8049. https://doi.org/10.1016/j.ejca.2024.114199.
2024 

Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma

Xia C, Krawczyk M, Di C, Krupa Ł, Kruk B, Krawczyk P, Milkiewicz P, Bao H, He X, Liu D, Fan C, Nasser A, Lopens S, Ulrich Weiss F, Frost F, Schierack P, Roggenbuck D, Liu Y.
Dig Liver Dis . 2024 Jun 8:S1590-8658(24)00785-0. doi: 10.1016/j.dld.2024.05.027
2024 

Strategies to enhance the response of liver cancer to pharmacological treatments

Marin JJG, Macias RIR, Asensio M, Romero MR, Temprano AG, Pereira OR, Jimenez S, Mauriz JL, Di Giacomo S, Avila MA, Efferth T, Briz O.
Am J Physiol Cell Physiol. 2024 May 6. doi: 10.1152/ajpcell.00176.2024.
2024 

Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic

Zanuso V, Nash T, Casolino R, Armstrong G, Pallise O, Milne J, Braconi C.
BMC Cancer 24, 597. 2024. https://doi.org/10.1186/s12885-024-12279-6
2024 
Join the Action
JOIN